乳腺癌的医学预防。
Medical prevention of breast cancer.
机构信息
Department of Obstetrics and Gynecology, University of Rostock, Germany.
出版信息
Breast Care (Basel). 2014 Dec;9(6):391-6. doi: 10.1159/000369573.
Abstract
Breast cancer is the most common cancer of women in Western Europe and North America. Effective strategies of medical prevention could reduce the burden of breast cancer mortality. The best evidence for a risk reduction exists for hormonal agents such as tamoxifen and raloxifene (22-72%) or aromatase inhibitors (50-65%). However, the severity of side effects and the lack of evidence for an improved survival compromise the risk/benefit balance. In this review the results of chemoprevention studies, including new treatment approaches, are summarized with critical discussion of their use in clinical practice.
摘要
乳腺癌是西欧和北美的女性最常见的癌症。有效的医学预防策略可以降低乳腺癌死亡率的负担。激素药物如他莫昔芬和雷洛昔芬（22-72%）或芳香酶抑制剂（50-65%）的风险降低证据最好。然而，副作用的严重程度和缺乏生存改善的证据影响了风险/效益平衡。在这篇综述中，总结了化学预防研究的结果，包括新的治疗方法，并对其在临床实践中的应用进行了批判性讨论。
相似文献
1
Medical prevention of breast cancer.乳腺癌的医学预防。
Breast Care (Basel). 2014 Dec;9(6):391-6. doi: 10.1159/000369573.
2
Current concepts in breast cancer chemoprevention.乳腺癌化学预防的当前概念。
Pol Arch Med Wewn. 2014;124(4):191-9. doi: 10.20452/pamw.2190. Epub 2014 Mar 10.
3
Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.选择性雌激素受体调节剂和芳香酶抑制剂用于乳腺癌化学预防。
Curr Drug Targets. 2011 Dec;12(13):1874-87. doi: 10.2174/138945011798184164.
4
Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.选择性雌激素受体调节剂：寻找理想的乳腺癌激素疗法。
Cancer Invest. 2001;19(6):649-59. doi: 10.1081/cnv-100104293.
5
Prevention of breast cancer using SERMs and aromatase inhibitors.使用选择性雌激素受体调节剂（SERM）和芳香化酶抑制剂预防乳腺癌
J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):5-18. doi: 10.1023/a:1025727103811.
6
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.美国临床肿瘤学会对降低乳腺癌风险的药物干预措施进行的技术评估，包括他莫昔芬、雷洛昔芬和芳香化酶抑制。
J Clin Oncol. 2002 Aug 1;20(15):3328-43. doi: 10.1200/JCO.2002.06.029.
8
Chemoprevention of breast cancer.乳腺癌的化学预防
Surg Clin North Am. 1999 Oct;79(5):1207-21. doi: 10.1016/s0039-6109(05)70069-4.
9
Breast Cancer Chemoprevention in an Integrated Health Care Setting.综合医疗环境中的乳腺癌化学预防
JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.16.00059.
10
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.药物预防乳腺癌的使用：美国预防服务工作组推荐声明。
JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885.
引用本文的文献
1
Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials.降低乳腺癌风险的药物：随机对照试验的网状Meta分析
Breast Cancer Res. 2025 Jul 1;27(1):118. doi: 10.1186/s13058-025-02059-w.
2
Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review.选择性雌激素受体调节剂在绝经前女性乳腺癌预防中的应用综述
Transl Cancer Res. 2020 Jul;9(7):4444-4456. doi: 10.21037/tcr-19-1956.
3
Risk-reducing medications for primary breast cancer: a network meta-analysis.原发性乳腺癌的风险降低药物：一项网状荟萃分析。
Cochrane Database Syst Rev. 2019 Apr 29;4(4):CD012191. doi: 10.1002/14651858.CD012191.pub2.
4
Decision making for breast cancer prevention among women at elevated risk.乳腺癌高危女性的预防决策
Breast Cancer Res. 2017 Mar 24;19(1):34. doi: 10.1186/s13058-017-0826-5.
5
The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.阿那曲唑和来曲唑对实验动物模型代谢谱的影响。
Sci Rep. 2015 Dec 1;5:17493. doi: 10.1038/srep17493.
6
The Promise of Preventive Cancer Vaccines.预防性癌症疫苗的前景
Vaccines (Basel). 2015 Jun 17;3(2):467-89. doi: 10.3390/vaccines3020467.
本文引用的文献
1
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.雌激素受体阴性乳腺癌预防性治疗的进展
Curr Breast Cancer Rep. 2014;6(2):96-109. doi: 10.1007/s12609-014-0144-1.
2
Breast cancer after chest radiation therapy for childhood cancer.儿童癌症胸部放疗后发生的乳腺癌。
J Clin Oncol. 2014 Jul 20;32(21):2217-23. doi: 10.1200/JCO.2013.54.4601. Epub 2014 Apr 21.
3
Molecular pathways: preclinical models and clinical trials with metformin in breast cancer.分子通路：二甲双胍在乳腺癌的临床前模型和临床试验。
Clin Cancer Res. 2014 May 15;20(10):2508-15. doi: 10.1158/1078-0432.CCR-13-0354. Epub 2014 Mar 28.
4
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.阿那曲唑预防绝经后高危女性乳腺癌（IBIS-II）：一项国际、双盲、随机、安慰剂对照试验。
Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.
5
Breast cancer chemoprevention: little progress in practice?乳腺癌化学预防：实际进展甚微？
Lancet. 2014 Mar 22;383(9922):1018-20. doi: 10.1016/S0140-6736(13)62555-6. Epub 2013 Dec 12.
6
Targeted therapy for breast cancer prevention.乳腺癌预防的靶向治疗。
Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250.
7
Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases.接触双膦酸盐与常见非胃肠道癌症风险：使用两个初级保健数据库的一系列嵌套病例对照研究。
Br J Cancer. 2013 Aug 6;109(3):795-806. doi: 10.1038/bjc.2013.383. Epub 2013 Jul 18.
8
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.应用药物干预降低乳腺癌风险：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8.
9
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.选择性雌激素受体调节剂在乳腺癌预防中的应用：一项个体参与者数据的更新荟萃分析。
Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30.
10
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.药物在降低原发性乳腺癌风险中的应用：美国预防服务工作组的系统评价。
Ann Intern Med. 2013 Apr 16;158(8):604-14. doi: 10.7326/0003-4819-158-8-201304160-00005.
Zotero 插件